CALC
CalciMedica, Inc.
$0.8670
-2.80%
$13.7M
No data for this timeframe.
Vol
Market Cap$13.7M
Cap SizeNano Cap
Inst. Holders10 funds
Inst. Value$223.8K
Inst. Activity1 buys / 1 sells
Reddit Sentiment63° Warm
SEC Reports3
Recent Activity
May 12, 2026
SEC
CalciMedica reported Q1 2026 GAAP net income of $5.0M ($0.31 basic EPS), a swing from a $5.0M net loss in Q1 2025, drive
8-K — Impact 4/10
Mar 12, 2026
SEC
CalciMedica, Inc. (CALC) has had an S-3 shelf registration statement declared effective by the SEC, allowing the company
EFFECT — Impact 4/10
Mar 3, 2026
SEC
CalciMedica filed an S-3 shelf registration, signaling potential future share issuance. The company has a market cap of
S-3 — Impact 6/10
Apr 5, 2025
Insider
Hebbar Sudarshan was granted 91,173 shares
Chief Medical Officer
Apr 5, 2025
Insider
Roberts Eric W was granted 83,358 shares
CHIEF BUSINESS OFFICER
Apr 5, 2025
Insider
Dunn Michael J. was granted 65,124 shares
President and COO
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
128,075 shares ($69.2K)
Inst.
Rockefeller Capital Management L.P. — TRIM
5,000 shares ($2.7K)
Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$10.33 (Mar 2026)
Current $0.8670
Low $6.00
Median $10.00
High $15.00
3 analysts
$6.00
$15.00
Analyst Ratings
3Strong Buy
5Buy
2Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 5, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| Jan 29, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.26 ▲ +9.2% | $-0.33 — $-0.22 | 34% YoY | 3 |
| Next Q | $-0.33 ▼ -9.3% | $-0.42 — $-0.22 | 36% YoY | 3 |
| Current FY | $-0.62 ▲ +50.0% | $-0.83 — $-0.37 | 69% YoY | 3 |
| Next FY | $-1.96 ▲ +9.3% | $-3.58 — $-0.86 | -217% YoY | 3 |
Latest Reports
NEUTRAL
8-K
4/10
CalciMedica reported Q1 2026 GAAP net income of $5.0M ($0.31 basic EPS), a swing from a $5.0M net loss in Q1 2025, drive
May 12, 2026
NEUTRAL
EFFECT
4/10
CalciMedica, Inc. (CALC) has had an S-3 shelf registration statement declared effective by the SEC, allowing the company
Mar 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $91.3K | — |
| RENAISSANCE TECHNOLOGIES LLC | $69.2K | ADD |
| VANGUARD FIDUCIARY TRUST CO | $24.7K | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $16.6K | — |
| CITADEL ADVISORS LLC | $9.8K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 5, 2025 | Hebbar Sudarshan | A | $0.00 |
| Apr 5, 2025 | Roberts Eric | A | $0.00 |
| Apr 5, 2025 | Dunn Michael | A | $0.00 |
| Apr 5, 2025 | Stauderman Kenneth | A | $0.00 |
| Apr 5, 2025 | Leheny A. | A | $0.00 |
Reddit Sentiment
63°
Warm
Bearish
Neutral
Bullish
10 institutional holders with $223.8K total value (454,020 shares) as of 2026-Q1. Top holders: VANGUARD, RENAISSANCE, VANGUARD.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 169,110 | $91.3K | 40.8% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 128,075 | $69.2K | 30.9% | ADD +45.0% |
| 3 | VANGUARD FIDUCIARY TRUST CO | 45,829 | $24.7K | 11.1% | — |
| 4 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 30,716 | $16.6K | 7.4% | — |
| 5 | CITADEL ADVISORS LLC | 18,200 | $9.8K | 4.4% | — |
| 6 | STATE STREET CORP | 17,073 | $9.2K | 4.1% | — |
| 7 | Rockefeller Capital Management L.P. | 5,000 | $2.7K | 1.2% | TRIM -50.0% |
| 8 | BROWN BROTHERS HARRIMAN & CO | 308 | $166.00 | 0.1% | — |
| 9 | HRT FINANCIAL LP | 39,699 | $21.00 | 0.0% | — |
| 10 | WELLS FARGO & COMPANY/MN | 10 | $5.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 88,300 | 128,075 | +45.0% | $69.2K | 2026-Q1 |
| Rockefeller Capital Management L.P. | TRIM | 10,000 | 5,000 | -50.0% | $2.7K | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 70,000 | 88,300 | +26.1% | $581.9K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 36,000 | 70,000 | +94.4% | $215.3K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 17,003 | 17 | -99.9% | $52.00 | 2025-Q3 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 59,047 | 93,433 | +58.2% | $149.5K | 2025-Q2 |
| UBS Group AG | DOUBLED | 220 | 17,003 | +7628.6% | $27.2K | 2025-Q2 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 46,552 | 59,047 | +26.8% | $112.8K | 2025-Q1 |
| UBS Group AG | TRIM | 325 | 220 | -32.3% | $421.00 | 2025-Q1 |
| VANGUARD GROUP INC | ADD | 254,148 | 339,148 | +33.4% | $1.2M | 2024-Q4 |
| Atria Investments, Inc | ADD | 26,503 | 34,012 | +28.3% | $120.4K | 2024-Q4 |
| UBS Group AG | DOUBLED | 15 | 325 | +2066.7% | $1.1K | 2024-Q4 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 22,256 | 43,631 | +96.0% | $193.3K | 2024-Q3 |
| Atria Investments, Inc | DOUBLED | 11,207 | 26,503 | +136.5% | $117.4K | 2024-Q3 |
6 unique insiders with 6 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 5, 2025 | Hebbar Sudarshan | Chief Medical Officer | AWARD | 91,173 | — | — |
| Apr 5, 2025 | Roberts Eric W | CHIEF BUSINESS OFFICER | AWARD | 83,358 | — | — |
| Apr 5, 2025 | Dunn Michael J. | President and COO | AWARD | 65,124 | — | — |
| Apr 5, 2025 | Stauderman Kenneth A. | Chief Scientific Officer | AWARD | 65,124 | — | — |
| Apr 5, 2025 | Leheny A. Rachel | CHIEF EXECUTIVE OFFICER | AWARD | 148,482 | — | — |
| Apr 5, 2025 | Bardin Stephen | Chief Financial Officer | AWARD | 67,728 | — | — |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 4.7/10.
NEUTRAL
8-K
4/10
CalciMedica reported Q1 2026 GAAP net income of $5.0M ($0.31 basic EPS), a swing from a $5.0M net lo
May 12, 2026
NEUTRAL
EFFECT
4/10
CalciMedica, Inc. (CALC) has had an S-3 shelf registration statement declared effective by the SEC,
Mar 12, 2026
BEARISH
S-3
6/10
CalciMedica filed an S-3 shelf registration, signaling potential future share issuance. The company
Mar 3, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Mar 2026): 80% buy across 10 analysts — 3 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$10.33 mean target (Mar 2026)
$6.00 Low
$15.00 High
| Metric | Value |
|---|---|
| Current Price | $0.8670 |
| Target Low | $6.00 |
| Target Mean | $10.33 |
| Target Median | $10.00 |
| Target High | $15.00 |
| # Analysts | 3 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.26 | $-0.33 | $-0.22 | 34.2% | +9.2% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.33 | $-0.42 | $-0.22 | 35.9% | -9.3% | 2↑ 0↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-0.62 | $-0.83 | $-0.37 | 68.7% | +50.0% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$-1.96 | $-3.58 | $-0.86 | -217.3% | +9.3% | 1↑ 2↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.263 | |
| 7d ago | $-0.290 | +0.027 |
| 30d ago | $-0.290 | +0.027 |
| 60d ago | $-0.290 | +0.027 |
| 90d ago | $-0.540 | +0.277 |
2 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 5, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Jan 29, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 2 | 0 | 0 | 80% | |
| May 1, 2026 | 3 | 5 | 2 | 0 | 0 | 80% | |
| Apr 1, 2026 | 3 | 5 | 2 | 0 | 0 | 80% | |
| Mar 1, 2026 | 3 | 5 | 2 | 0 | 0 | 80% | |
| Feb 1, 2026 | 3 | 5 | 2 | 0 | 0 | 80% | |
| Jan 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
63°
Warm
Bearish
Neutral
Bullish
4 mentions
2 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 7, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 7, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 7, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 7, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 18, 2026
earnings_calendar
CALC Q1 2026 Earnings Scheduled — 2026-05-18
Apr 1, 2026
Clinical Trial
A Study of Auxora in Patients With Critical COVID-19 Pneumonia
Phase Phase 2 — TERMINATED
Apr 1, 2026
Clinical Trial
A Study of Auxora in Patients With Severe COVID-19 Pneumonia
Phase Phase 2 — COMPLETED
Apr 1, 2026
Clinical Trial
CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS
Phase Phase 2 — COMPLETED